Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Dec 1;88(4):340–347. doi: 10.1097/QAI.0000000000002781

Table 4.

HIV Outcomes Associated with Increasing Levels of PrEP Coverage, Stratified by the Proportion of Virally Suppressed Among the Infected. For Each ART Baseline (Low, Empirical, High) PIA and NNT Are Calculated Using the no PrEP Scenario of the Baseline

Scenario Low ART (51.2 % Viral Suppression) Empirical ART (60% Viral Suppression) High ART (72.9% Viral Suppression)
NIA2 PIA3 NNT4 NIA2 PIA3 NNT4 NIA2 PIA3 NNT4
Median (95% SI 1 ) Median (95% SI 1 ) Median (95% SI 1 ) Median (95% SI 1 ) Median (95% SI 1 ) Median (95% SI 1 ) Median (95% SI 1 ) Median (95% SI 1 ) Median (95% SI 1 )
PrEP Target
 No PrEP (reference) - - - - - - - - -
 12.5% 178 (67, 294) 12% (5%, 20%) 36 (22, 90) 169 (46, 282) 16% (4%, 27%) 45 (26, 136) 141 (9, 252) 23% (1%, 42%) 64 (35, 435)
 25.0% (SFO Level) 362 (264, 477) 25% (18%, 33%) 36 (27, 49) 326 (217, 419) 31% (20%, 39%) 48 (37, 71) 251 (154, 331) 42% (25%, 55%) 75 (57, 120)
 37.5% 516 (425, 594) 35% (29%, 41%) 37 (33, 44) 449 (370, 529) 42% (35%, 50%) 51 (43, 61) 326 (250, 392) 54% (41%, 65%) 85 (71, 109)
 50.0% 664 (580, 738) 46% (40%, 51%) 38 (35, 43) 557 (490, 628) 52% (46%, 59%) 54 (48, 61) 386 (321, 437) 64% (53%, 72%) 94 (83, 113)
 62.5% 798 (729, 860) 55% (50%, 59%) 40 (37, 43) 656 (596, 712) 62% (56%, 67%) 57 (53, 62) 425 (381, 469) 70% (63%, 78%) 106 (96, 117)
 75.0% 892 (834, 953) 61% (57%, 66%) 41 (38, 43) 720 (674, 765) 68% (64%, 72%) 60 (56, 64) 455 (413, 488) 75% (68%, 81%) 113 (106, 124)
1

Simulation Interval.

2

Number of infections averted over the 10-year intervention relative to the reference scenario.

3

Percent of infections averted over the 10-year intervention relative to the reference scenario.

4

Number of additional person-years needed to treat by PrEP to avert one infection over the 10-year intervention relative to the reference scenario.